People · Operator

Adam E. Buckley

Named in public records as an officer, director or promoter · active 2013–2013 · Biotechnology

1
Companies
3
Filings
$17.1M
Combined raised · real
Single
Operator type
Companies
CompanyRoleSectorStageRaised · realValue · estTied
Variation Biotechnologies (US), Inc.BiotechnologySeries A$17.1M$54.2M2013
Operator network

Adam E. Buckley at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.

Steven Gillis · 23 companies · 1 sharedSteven GillisSteve Gillis · 13 companies · 1 sharedSteve GillisSCOTT ROCKLAGE · 9 companies · 1 sharedSCOTT ROCKLAGEJeff Baxter · 4 companies · 1 sharedJeff BaxterJeffrey Leiden · 4 companies · 1 sharedJeffrey LeidenMichael Steinmetz · 4 companies · 1 sharedMichael SteinmetzDavid E. Anderson · 3 companies · 1 sharedDavid E. AndersonEgidio Nascimento · 3 companies · 1 sharedEgidio NascimentoKevin Forrest · 3 companies · 1 sharedKevin ForrestStephen Gillis · 2 companies · 1 sharedStephen GillisMarc J. Kirchmeier · 1 companies · 1 sharedMarc J. KirchmeierSteve E. Vignau · 1 companies · 1 sharedSteve E. VignauSTEVEN VIGNAU · 1 companies · 1 sharedSTEVEN VIGNAUSteve Vignau · 1 companies · 1 sharedSteve VignauVariation Biotechnologies (US), Inc. · $17.1M raisedVariation Biotechnolo…Adam E. BuckleyAB
Adam E. Buckley Company Co-operator (ring = serial)Hover to isolate ties · click to open
Co-operators (shared boards)

People named alongside Adam E. Buckley on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.

OperatorSharedTheir companies
Steven Gillis123
Steve Gillis113
SCOTT ROCKLAGE19
Michael Steinmetz14
Jeff Baxter14
Jeffrey Leiden14
Kevin Forrest13
Egidio Nascimento13
David E. Anderson13
Stephen Gillis12
Steve Vignau11
Marc J. Kirchmeier11
Steve E. Vignau11
STEVEN VIGNAU11

People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.